Team

Prior to joining ABio-X, Sean was a Managing Director of CBC Group, co-founded and served as the CEO of Everest Medicines and was the VP of Global Business Development at Simcere Pharmaceutical Group. Sean was also the President and Board Director at Simcere America, a wholly owned subsidiary. Previously, Sean was the Senior Director of Alternative Partnerships, Evaluation & Expertise at Sanofi. Before Sanofi, Sean was an Associate at New Leaf Venture Partners, a healthcare VC firm. Earlier in his career, Sean worked in the pharmaceutical and diagnostic industries at Aventis and Johnson & Johnson. Sean currently serves as the Chairman of NiKang Therapeutics. He holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a Bachelor of Science in Microbiology from Nankai University, China. 

Joanna has practiced law since 2003, with an initial focus on patent and FDA regulatory matters and later in other areas including corporate and technology transactions.  She began her career with Ropes & Gray in Boston, followed by in-house experience in various medical device and biotechnology companies.  She received her JD from University of California, Berkeley with a Certificate in Law and Technology, and she was on the editorial boards of the California Law Review and Berkeley Technology Law Journal. As a registered U.S. patent attorney, Joanna also has a technical background with a PhD in physiology from the University of Virginia and conducted research at the Lawrence Berkeley National Laboratory as a recipient of the Alexander Hollaender Distinguished Postdoctoral Fellowship from the U.S. Department of Energy.

Sean Fu is an experienced leader and proven entrepreneur. Sean was co-founder and CEO of RVAC Medicines, an mRNA company established in 2021, raised $170 million and successfully brought two COVID vaccines into clinical study.
Prior to founding RVAC, Sean was Group VP and head of International R&D of Luye Pharma, overseeing organizations in Boston, Princeton, Germany, Switzerland and Japan. He was also the founding CEO of GeneLeap, a Luye subsidiary company focusing on DNA and RNA therapeutics.
Previously, Sean worked at Merck & Co. for 15 years with increasing responsibilities covering R&D, business development, and finance. He managed the finances of a $300 million late-stage clinical portfolio and led the integration of global R&D network after the landmark $42 billion merger between Merck and Schering-Plough.
His numerous honors included Merck & Co’s highest award for R&D innovation—the Best Business Value Award (2005); The Ohio State University William Oxley Thompson Alumni Award (2006), College of Engineering Distinguished Alumni Award (2022) and the Materials Research Society (MRS) Gold Award for Research (2000).
Sean earned a PhD in materials science and engineering from the Ohio State University, and an MBA from Wharton School of University of Pennsylvania.

Prior to joining ABio-X, Tracy was Senior Director of Strategy and Business Development at RVAC Medicines, an innovative mRNA company. Previously, Tracy served as Director of Consulting at ChinaBio Group, where she led more than 50 consulting projects assisting US and European companies to develop global and Asia-specific product development, partnership, and commercialization strategies. Tracy received her postdoctoral training at UCLA under Dr. Dale Bredesen and at UCSF under Dr. Frank Longo, and was a recipient of the NIH Shannon Director’s Award and a fellowship from the John Douglas French Alzheimer's Foundation. Tracy holds a BS from National Taiwan University and a PhD in Biomedical Sciences from Mount Sinai School of Medicine/CUNY.